bluebird bio Inc $ 79.42 -1.23 (-1.53%)
Volume:
984,485
Avg Vol (1m):
954,308
Market Cap $:
4.39 Bil
Enterprise Value $:
3.41 Bil
P/E (TTM):
0.00
P/B:
2.97
| Earnings Power Value | ||
| Net Current Asset Value | ||
| Tangible Book | ||
| Projected FCF | ||
| Median P/S Value | ||
|
Price: $79.42 | ||
Manual of Stocks™ Web
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 6.02 | ||
| Equity-to-Asset | 0.78 | ||
| Debt-to-Equity | 0.13 | ||
| Debt-to-EBITDA | -0.27 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 4.61 | ||
| Beneish M-Score | -2.13 | ||
Profitability | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -1368.3 | ||
| Net Margin % | -1326.57 | ||
| ROE % | -40.8 | ||
| ROA % | -33.59 | ||
| ROC (Joel Greenblatt) % | -257.26 | ||
| 3-Year Revenue Growth Rate | 37.2 | ||
| 3-Year EBITDA Growth Rate | -32.3 | ||
| 3-Year EPS without NRI Growth Rate | -30.5 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 2.97 | ||
| PS Ratio | 80.95 | ||
| EV-to-EBIT | -4.62 | ||
| EV-to-EBITDA | -4.72 | ||
| EV-to-Revenue | 63.22 | ||
| Current Ratio | 6.22 | ||
| Quick Ratio | 6.22 | ||
| Days Sales Outstanding | 88.98 | ||
| Days Payable | 5612.93 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 3.04 | ||
| Price-to-Median-PS-Value | 0.54 | ||
| Earnings Yield (Greenblatt) % | -21.65 |